Alectinib eclipses crizotinib for ALK positive lung cancer
5 Jun 2017
Alectinib eclipses crizotinib for ALK positive lung cancer
New personalised therapies for lung cancer
Dose escalation results of ceritinib and nivolumab for ALK NSCLC
Nivolumab for NSCLC: five years on
Five-year follow-up of nivolumab in NSCLC
Olaparib and temozolomide for relapsed small cell lung cancer
Surgery over SBRT for early lung cancer
SBRT or surgery for early lung cancer?
Tobacco, lung cancer and non-smoking lung cancers
Screening for lung cancer - current status and recommendations
Advances in image contouring
Cimavax - a lung cancer vaccine